Is Blackrock 2037 Municipal Target Term Trust (BMN) a Buy, Sell, or Hold?
NYSE : BMN
Blackrock 2037 Municipal Target Term Trust
$25.45 USD
-$0.06 (-0.24%)
- Volume
- 6.79K
- Average Volume
- 9.3K
- Market Capitalization
- $156.46M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $27.96
- Year Low
- $23.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia SAN RAFAEL, Calif., June 16, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago. prnewswire.com - 2026-06-16 09:05:00 |
|
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study's other co-primary endpoint and an important clinical measure of change in rickets severity Company is evaluating data to determine next steps SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition. prnewswire.com - 2026-05-18 09:05:00 |
|
Bitcoin surged in April, but weak buyer demand makes the rally vulnerable
Bitcoin gained 12.7% in April, registering back-to-back monthly gains and its best month since April 2025. The run was driven by leveraged trading activity in the derivatives market while demand for the spot bitcoin contracted, signaling weakness in the rally, according to CryptoQuant. cnbc.com - 2026-05-01 11:57:34 |
